Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

415 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers.
Brouckaert O, Laenen A, Vanderhaegen J, Wildiers H, Leunen K, Amant F, Berteloot P, Smeets A, Paridaens R, Christiaens MR, Floris G, Moerman P, Van Limbergen E, Peeters S, Weltens C, Vergote I, Neven P. Brouckaert O, et al. Among authors: wildiers h. Ann Oncol. 2012 Oct;23(10):2578-2584. doi: 10.1093/annonc/mds062. Epub 2012 Apr 6. Ann Oncol. 2012. PMID: 22492698 Free article.
Detection of micrometastatic disease and monitoring of perioperative tumor cell dissemination in primary operable breast cancer patients using real-time quantitative reverse transcription-PCR.
Ismail MS, Wynendaele W, Aerts JL, Paridaens R, Gaafar R, Shakankiry N, Khaled HM, Christiaens MR, Wildiers H, Omar S, Vandekerckhove P, Van Oosterom AT. Ismail MS, et al. Among authors: wildiers h. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):196-201. doi: 10.1158/1078-0432.ccr-0515-2. Clin Cancer Res. 2004. PMID: 14734470
Taxanes in elderly breast cancer patients.
Wildiers H, Paridaens R. Wildiers H, et al. Cancer Treat Rev. 2004 Jun;30(4):333-42. doi: 10.1016/j.ctrv.2003.12.001. Cancer Treat Rev. 2004. PMID: 15145508 Review.
Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view.
Neven P, Paridaens R, Amant F, Wildiers H, Berteloot P, Leunen K, Smeets A, Weltens C, van den Bogaert W, van Limbergen E, Christiaens MR, Vergote I. Neven P, et al. Among authors: wildiers h. Int J Gynecol Cancer. 2006;16 Suppl 2:505-10. doi: 10.1111/j.1525-1438.2006.00682.x. Int J Gynecol Cancer. 2006. PMID: 17010059 Review. No abstract available.
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
Perey L, Paridaens R, Hawle H, Zaman K, Nolé F, Wildiers H, Fiche M, Dietrich D, Clément P, Köberle D, Goldhirsch A, Thürlimann B. Perey L, et al. Among authors: wildiers h. Ann Oncol. 2007 Jan;18(1):64-69. doi: 10.1093/annonc/mdl341. Epub 2006 Oct 9. Ann Oncol. 2007. PMID: 17030543 Free article. Clinical Trial.
415 results